Varian TrueBeam
September 30, 2013 – IMRIS Inc. and Varian Medical Systems presented data at the American Society for Radiation Oncology (ASTRO) Annual Meeting demonstrating the potential to direct state-of-the-art radiation treatments using diagnostic-quality magnetic resonance (MR) images at each treatment session.
In a presentation to radiation oncology clinicians from around the globe, David Jaffray, Ph.D., radiation physicist at the Princess Margaret Cancer Centre and Director of the Techna Institute at the University Health Network (UHN) in Toronto, described a dedicated MR-guided radiation therapy suite that will allow a MR scanner mounted on ceiling rails to perform MR-guided brachytherapy and external beam radiation delivery. Currently being installed at his institution, this combination is a joint development combining IMRIS' MR imaging with Varian's TrueBeam system for image-guided radiotherapy and radiosurgery.
"Tightly integrating MR imaging with treatment is expected to allow us to increase the accuracy of radiation delivery and pursue research in the emerging field of adaptive radiation therapy — the next level of image-guided radiotherapy that seeks to modify the treatment in response to changes in patient anatomy," said Jaffray. The team at the Princess Margaret has been performing research on the use of MR in radiation therapy as well as studying how the MR and radiation treatment technologies can be made compatible.
"While it is premature to speak to the clinical benefits of the development," he added, "the technical advantage of enhanced visualization of the tumor and normal tissues at the time of treatment opens many possibilities." The Princess Margaret team is planning to explore the system's use in the treatment of prostate, gynecological, and liver cancers, he said.
IMRIS and Varian are co-developing the MR-guided radiation therapy system that combines IMRIS's proprietary MR imaging technology with Varian's TrueBeam system to enable the use of MR imaging during radiotherapy treatments for cancer. The two companies are collaborating with the team at The Princess Margaret Cancer Centre and UHN's Techna Institute in Toronto to develop the system, which is not cleared for sale in any jurisdiction at this time.
For more information: www.varian.com
August 09, 2024 
